Paper published in a journal (Scientific congresses and symposiums)
Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC)
van Puijenbroek, R.; Bosquee, Léon; Tits, G. et al.
2005In Lung Cancer, 49 (Suppl. 2), p. 273
Peer Reviewed verified by ORBi
 

Files


Full Text
Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1....pdf
Publisher postprint (301.01 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Disciplines :
Cardiovascular & respiratory systems
Oncology
Author, co-author :
van Puijenbroek, R.
Bosquee, Léon ;  Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie
Tits, G.
Germonpre, P.
Strobbe, E.
Vansteenkiste, J.
Language :
English
Title :
Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC)
Publication date :
July 2005
Audience :
International
Journal title :
Lung Cancer
ISSN :
0169-5002
eISSN :
1872-8332
Publisher :
Elsevier Ireland Ltd, Clare, Ireland
Volume :
49
Issue :
Suppl. 2
Pages :
S273
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 27 January 2011

Statistics


Number of views
23 (1 by ULiège)
Number of downloads
54 (1 by ULiège)

Bibliography


Similar publications



Contact ORBi